Literature DB >> 23289476

Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer.

Chunyan Lan1, Xin Huang, Suxia Lin, Huiqiang Huang, Qichun Cai, Ting Wan, Jiabin Lu, Jihong Liu.   

Abstract

Macrophages are polarized into two functionally distinct forms, M1 and M2, in response to different microenvironment. Tumor-associated macrophages (TAMs) generally have M2 phenotype and promote tumor progression. Few studies to date have described the infiltration of M2-polarized macrophages in ovarian cancer. We used two macrophages markers, CD68 and CD163, to analyze the expression of TAMs and to clarify the relationship between the M2 form and survival in advanced ovarian cancer. Clinical data of 110 patients with stages III-IV epithelial ovarian cancer at Sun Yat-sen University Cancer Center between 1999 and 2007 were retrospectively reviewed. Immunohistochemical staining of CD68 and CD163 was performed. Correlations between macrophage density and patient survival were analyzed. Our data showed that no significant difference was observed in survival between patients in the high- and the low-CD68 expression groups. In contrast, the progression-free survival (PFS) rates (p = 0.003) and overall survival (OS) rates (p = 0.004) were significantly higher in the low-CD163 expression group than in the high-CD163 expression group, respectively. Similarly, we also observed significantly improved 3-year PFS (49.8% vs. 11.0%, p < 0.001) and OS (77.4% vs. 45.0%, p < 0.001) rates in patients in the low-CD163/CD68 ratio group when compared with the high-CD163/CD68 ratio group. Multivariate analysis identified the density of CD163-positive cells as well as the ratio of CD163/CD68 as negative predictors for PFS and OS, respectively. Our results show that the infiltration of CD163-positive M2 macrophages as well as activation of macrophages towards the M2 phenotype may contribute to poor survival in advanced ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23289476     DOI: 10.7785/tcrt.2012.500312

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  91 in total

1.  Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Authors:  Keith L Knutson; Matthew J Maurer; Claudia C Preston; Kirsten B Moysich; Krista Goergen; Kieran M Hawthorne; Julie M Cunningham; Kunle Odunsi; Lynn C Hartmann; Kimberly R Kalli; Ann L Oberg; Ellen L Goode
Journal:  Cancer Immunol Immunother       Date:  2015-08-23       Impact factor: 6.968

Review 2.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

3.  M2 macrophages do not fly into a "RAGE".

Authors:  Armando Rojas; Carolina Añazco; Paulina Araya
Journal:  Inflamm Res       Date:  2016-10-03       Impact factor: 4.575

Review 4.  Mathematical modeling of tumor-immune cell interactions.

Authors:  Grace E Mahlbacher; Kara C Reihmer; Hermann B Frieboes
Journal:  J Theor Biol       Date:  2019-03-02       Impact factor: 2.691

5.  Macrophage polarization differs between apical granulomas, radicular cysts, and dentigerous cysts.

Authors:  Manuel Weber; Tilo Schlittenbauer; Patrick Moebius; Maike Büttner-Herold; Jutta Ries; Raimund Preidl; Carol-Immanuel Geppert; Friedrich W Neukam; Falk Wehrhan
Journal:  Clin Oral Investig       Date:  2017-05-13       Impact factor: 3.573

6.  Characterization of the immune cell repertoire in the normal fallopian tube.

Authors:  Laura Ardighieri; Silvia Lonardi; Daniele Moratto; Fabio Facchetti; Ie-Ming Shih; William Vermi; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2014-11       Impact factor: 2.762

Review 7.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

8.  Proangiogenic TIE2(+)/CD31 (+) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes.

Authors:  Ok-Hee Kim; Gun-Hyung Kang; Hyungjoon Noh; Ji-Young Cha; Ho-Jae Lee; Jeong-Hwan Yoon; Mizuko Mamura; Jeong-Seok Nam; Dae Ho Lee; Young A Kim; Young Joo Park; Hyeonjin Kim; Byung-Chul Oh
Journal:  Mol Cells       Date:  2013-10-24       Impact factor: 5.034

Review 9.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

10.  Evaluation of a nanotechnology-based approach to induce gene-expression in human THP-1 macrophages under inflammatory conditions.

Authors:  Laura Bernal; Abigail Alvarado-Vázquez; David Wilson Ferreira; Candler A Paige; Cristina Ulecia-Morón; Bailey Hill; Marina Caesar; E Alfonso Romero-Sandoval
Journal:  Immunobiology       Date:  2016-09-05       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.